| CAS |
No.849479-74-9 |
| 中文名称 |
醋酸伐普肽 |
| 英文名称 |
Vapreotide Acetate |
| 分子式 |
C59H74N12O11S2 |
| 分子量 |
1191.42 |
| 溶解性 |
Soluble in Water ≥1mg/mL |
| 纯度 |
≥98% |
| 外观(性状) |
White to off-white Solid |
| 储存条件 |
Powder:-20℃，1 year;Insolvent(母液):-20℃，6 months;-80℃，1 year |
| 运输条件 |
冷藏运输 |
| 靶点 |
Neurokinin Receptor |
| 通路 |
GPCR & G Protein;Neuronal Signaling |
| 背景说明 |
Vapreotide acetate 是神经激肽-1 (NK1) 受体拮抗剂。 |
| 生物活性 |
Vapreotide acetate (RC-160 acetate; BMY-41606 acetate) is a neurokinin-1 (NK1) receptor antagonist， with an IC50 of 330 nM.[1-5] |
| In Vitro |
Vapreotide attenuates the Substance P (SP)-triggered intracellular calcium increases and NF-κB activation in a dose-dependent manner. Vapreotide also inhibits SP-induced IL-8 and MCP-1 production in HEK293-NK1R and U373MG cell lines. Vapreotide inhibits HIV-1 infection of human MDM in vitro， an effect that is reversible by SP pretreatment[1]. Vapreotide significantly inhibits GH-， PRL， and/or alpha-subunit release by human GH-secreting pituitary adenoma cells in concentrations as low as 10-12-10-14 M. Vapreotide inhibits GH release with an IC50 of 0.1 pM[2]. Vapreotide exhibits moderate-to-high affinities for SSTR2， -3， and -5 (IC50=0.17， 0.1 and 21 nM， respectively) and low affinity for SSTR1 and -4 (IC50=200 and 620 nM， respectively). RC-160 inhibits serum-induced proliferation of CHO cells expressing SSTR2 and SSTR5 (EC50=53 and 150 pM， respectively)[3]. |
| In Vivo |
In cirrhosis， bleeding by rupture of oesophagogastric varices is a severe complication of portal hypertension. The acute administration of vapreotide to rats decreases collateral circulation blood flow while chronic administration attenuated its development[4]. Tumor volumes and weights are reduced by about 40% by RC-160 by s.c. injections at doses of 100 μg/day/animal. Vapreotide can inhibit the growth of androgen-independent prostate cancer when the therapy is started at an early stage of tumor development[5]. |
| 细胞实验 |
CHO cells are cultured in aMEM containing 10% FCS. After overnight attachment， the medium is changed to a MEM containing either 10% FCS or insulin with and without vapreotide. Cell growth is measured after 24 h by counting cells with a Coulter counter model ZM[3]. |
| 动物实验 |
Rats: Acute effects are evaluated at baseline and 30 min after placebo or vapreotide (8 μg/kg/hr) infusions in DMNA rats. Chronic hemodynamic effects are evaluated using subcutaneous implants for five weeks in anesthetized DMNA rats and in sham rats. Hemodynamic measurements include splenorenal shunt blood flow by the transit time ultrasound method and cardiac output by the combined dilution–TTU method[4]. Mice: Nude mice bearing xenografts of the androgen-independent human prostate-cancer cell line PC-3 are treated for 4 weeks with somatostatin analog vapreotide (20 μg/day/animal)， bombesin/gastrin-releasing peptide (GRP) antagonist， or the combination of both peptides. Tumor volumes and weights are measured[5]. |
| 数据来源文献 |
[1]. Spitsin S， et al. Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor. Neuroimmunomodulation. 2013;20(5):247-55.
[2]. Hofland LJ， et al. Relative potencies of the somatostatin analogs octreotide， BIM-23014， and RC-160 on theinhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Endocrinology. 1994 Jan;134(1):301-6.
[3]. Buscail L， et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci U S A. 1995 Feb 28;92(5):1580-4.
[4]. Veal N， et al. Hemodynamic effects of acute and chronic administration of vapreotide in rats with cirrhosis. Dig Dis Sci. 2003 Jan;48(1):154-61.
[5]. Pinski J， et al. Effect of somatostatin analog RC-160 and bombesin/gastrin releasing peptide antagonist RC-3095 on growth of PC-3 human prostate-cancer xenografts in nude mice. |
| 规格 |
1mg 5mg 10mg 25mg 50mg |
| 单位 |
瓶 |
中文
英语
说明书下载
京公网安备 11011202000391号